This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2022 Nov;97(11):E416-E419.

doi: 10.1002/ajh.26692. Epub 2022 Sep 16.

Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A

Keith W Pratz¹, Courtney D DiNardo², Dominik Selleslag³, Junmin Li⁴, Kazuhito Yamamoto⁵, Marina Konopleva², Don Stevens⁶, Hagop Kantarjian², Fabiola Traina⁷, Adriano Venditti⁸, Jiri Mayer⁹, Melissa Montez¹⁰, Huan Jin¹⁰, Yinghui Duan¹¹, Deanna Brackman¹¹, Jiuhong Zha¹¹, Jalaja Potluri¹¹, Michael Werner¹¹, Brian A Jonas¹²

Affiliations

Affiliations

¹ Department of Medicine, Hematology-Oncology Section, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
³ Algemeen Ziekenhuis Sint Jan, Brugge-Oostende, Belgium.
⁴ Ruijin Hospital, Shanghai, China.
⁵ Aichi Cancer Center, Chikusa-ku, Nagoya, Japan.
⁶ Norton Cancer Institute, Louisville, Kentucky, USA.
⁷ Department of Medical Imaging, Haematology, and Oncology, University of São Paulo at Ribeirão Preto Medical School, Sao Paulo, Brazil.
⁸ Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
⁹ University Hospital Brno and Masaryk University, Brno, Czech Republic.
¹⁰ Genentech, Inc, South San Francisco, California, USA.
¹¹ AbbVie, Inc, North Chicago, Illinois, USA.
¹² Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, California, USA.

PMID: 36054316
DOI: 10.1002/ajh.26692

Free article

Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A

Keith W Pratz et al. Am J Hematol. 2022 Nov.

Free article

. 2022 Nov;97(11):E416-E419.

doi: 10.1002/ajh.26692. Epub 2022 Sep 16.

Authors

Keith W Pratz¹, Courtney D DiNardo², Dominik Selleslag³, Junmin Li⁴, Kazuhito Yamamoto⁵, Marina Konopleva², Don Stevens⁶, Hagop Kantarjian², Fabiola Traina⁷, Adriano Venditti⁸, Jiri Mayer⁹, Melissa Montez¹⁰, Huan Jin¹⁰, Yinghui Duan¹¹, Deanna Brackman¹¹, Jiuhong Zha¹¹, Jalaja Potluri¹¹, Michael Werner¹¹, Brian A Jonas¹²

Affiliations

¹ Department of Medicine, Hematology-Oncology Section, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
³ Algemeen Ziekenhuis Sint Jan, Brugge-Oostende, Belgium.
⁴ Ruijin Hospital, Shanghai, China.
⁵ Aichi Cancer Center, Chikusa-ku, Nagoya, Japan.
⁶ Norton Cancer Institute, Louisville, Kentucky, USA.
⁷ Department of Medical Imaging, Haematology, and Oncology, University of São Paulo at Ribeirão Preto Medical School, Sao Paulo, Brazil.
⁸ Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
⁹ University Hospital Brno and Masaryk University, Brno, Czech Republic.
¹⁰ Genentech, Inc, South San Francisco, California, USA.
¹¹ AbbVie, Inc, North Chicago, Illinois, USA.
¹² Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, California, USA.

PMID: 36054316
DOI: 10.1002/ajh.26692

No abstract available

PubMed Disclaimer

References

REFERENCE

1. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-629.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information